Updated offers covering Antibiotics, Aminoglycosides, Cephalosporin, Clindamycin, Macrolides, Penici



DUBLIN – (BUSINESS WIRE) – The report “Global Antibiotics Partnership Terms and Agreements 2010-2020” has been added to ResearchAndMarkets.com offer.

The Global Antibiotics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to antibiotics partnership agreements and agreements entered into by the world’s leading healthcare companies.

The report provides detailed understanding and analysis of how and why companies are entering into antibiotics partnership agreements. The majority of agreements are at the early stage of development whereby the licensee obtains a right or option right to license the antibiotic technology or product candidates from the licensor. These agreements tend to be multi-component, starting with collaborative R&D and the commercialization of results.

Understanding the flexibility of the terms of the agreements negotiated by a potential partner provides critical insight into the negotiation process in terms of what you can expect to achieve when negotiating the terms. While many small businesses will be looking for details on payment terms, the devil is in the detail in terms of triggering payments – contract documents provide that insight where press releases and databases do not.

This report contains over 300 links to online copies of antibiotic offerings and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to many questions about a potential partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the agreement.

Scope of the report

Global Antibiotics Partnership Terms and Agreements from 2010 to 2020 include:

  • Trends in antibiotics trading in the biopharmaceutical industry since 2010

  • Analysis of the structure of agreements on antibiotics

  • Access to title, advance, milestone and royalty data

  • Case studies of actual antibiotic offerings

  • Access to over 300 antibiotic agreement files and contractual documents, where applicable

  • The main antibody transactions by value since 2010

  • The most active antibiotics traders since 2010

  • The main partnership resources for antibiotics

In the 2010-2020 Global Antibiotics Partnership Terms and Agreements, the available contracts are listed by:

  • Company from A to Z

  • Title value

  • Stage of development at signing

  • Component type of the agreement

  • Specific therapeutic and technological target

This report details the latest antibiotic deals announced in healthcare sectors, covering:

  • Antibiotics

  • Aminoglycosides

  • Cephalosporin

  • Clindamycin

  • Macrolides

  • Penicillin

  • Quinolones

  • Sulfonamides

  • Tetracycline

Main topics covered:


Chapter 1 Introduction

Chapter 2 – Trends in Antibiotics Trading

2.1. introduction

2.2. Antibiotics in partnership over the years

2.3. The most active antibiotics negotiators

2.4. Antibiotic partnership by type of agreement

2.5. Antibiotic partnership by therapeutic area

2.6. Antibiotics partnership by sector of activity

2.7. Terms of Agreement for Antibiotics Partnership

2.7.1 Key values ​​of the antibiotics partnership

2.7.2 Upfront payments for antibiotics

2.7.3 Milestone Payments for Antibiotics

2.7.4 Antibiotic royalty rate

2.8. The anatomy of an antibiotic case

2.8. a. Case study 1: RRD International and Dipexium Pharmaceuticals

2.8.b. Case Study 2: Hospira & Cempra Pharmaceutical

2.8.c. Case Study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 – The Best Antibiotic Deals

3.1. introduction

3.2. Best Antibiotic Deals By Value

Chapter 4 – The Most Active Antibiotics Traders

4.1. introduction

4.2. The most active antibiotics negotiators

4.3. Profiles of the most active antibiotic partner companies

Chapter 5 – Directory of negotiation of antibiotics contracts

5.1. introduction

5.2. Antibiotics contract negotiation directory

Chapter 6 – Antibiotic Transactions by Type of Technology

  • Antibiotics

  • Aminoglycosides

  • Cephalosporin

  • Clindamycin

  • Macrolides

  • Metronidazole

  • Penicillin

  • Quinolones

  • Tetracycline

Chapter 7 – Partner Resource Center

7.1. Online partnership

7.2. Partnership events

7.3. Further reading on negotiation

For more information on this report, visit https://www.researchandmarkets.com/r/i1wtx9



Laura Wood, Senior Press Director


For EST office hours, call 1-917-300-0470

For USA / CAN call toll free 1-800-526-8630

For GMT office hours, call + 353-1-416-8900

Copyright © acrofan / Business Wire All rights reserved

Source link


Leave A Reply